Snowden Capital Advisors LLC Buys 842 Shares of Perrigo Company plc (NYSE:PRGO)

Snowden Capital Advisors LLC boosted its stake in Perrigo Company plc (NYSE:PRGO) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,337 shares of the company’s stock after purchasing an additional 842 shares during the period. Snowden Capital Advisors LLC’s holdings in Perrigo were worth $626,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barclays PLC lifted its stake in Perrigo by 44.8% in the 3rd quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after purchasing an additional 37,268 shares during the last quarter. Access Investment Management LLC bought a new position in Perrigo in the 4th quarter valued at approximately $7,989,000. Charles Schwab Investment Management Inc. lifted its stake in Perrigo by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,048,005 shares of the company’s stock valued at $26,944,000 after purchasing an additional 13,835 shares during the last quarter. Raymond James Financial Inc. bought a new position in Perrigo in the 4th quarter valued at approximately $3,177,000. Finally, SG Americas Securities LLC bought a new position in Perrigo in the 4th quarter valued at approximately $691,000. Institutional investors own 95.91% of the company’s stock.

Insider Transactions at Perrigo

In related news, EVP Ronald Craig Janish sold 7,800 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $27.44, for a total transaction of $214,032.00. Following the transaction, the executive vice president now directly owns 33,666 shares of the company’s stock, valued at $923,795.04. This represents a 18.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Perrigo currently has an average rating of “Hold” and an average target price of $33.00.

Perrigo Trading Up 0.8%

Shares of NYSE PRGO opened at $27.42 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. Perrigo Company plc has a 52-week low of $23.14 and a 52-week high of $30.93. The firm has a 50 day moving average price of $26.26 and a two-hundred day moving average price of $26.17. The stock has a market cap of $3.77 billion, a P/E ratio of -23.44 and a beta of 0.45.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.04. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company posted $0.29 EPS. The company’s revenue was down 3.5% on a year-over-year basis. As a group, equities analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 4.23%. The ex-dividend date is Friday, May 30th. Perrigo’s dividend payout ratio (DPR) is presently -88.55%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.